Comments
Loading...

Oncternal Therapeutics

ONCTNASDAQ
Logo brought to you by Benzinga Data
$1.67
0.010.91%
Last update: 10:28 AM
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$18.00
Lowest Price Target1
$1.30
Consensus Price Target1
$6.58

Oncternal Therapeutics (NASDAQ:ONCT) Stock, Analyst Ratings, Price Targets, Forecasts

Oncternal Therapeutics Inc has a consensus price target of $6.58 based on the ratings of 7 analysts. The high is $18 issued by HC Wainwright & Co. on August 12, 2024. The low is $1.3 issued by Cantor Fitzgerald on September 7, 2023. The 3 most-recent analyst ratings were released by Northland Capital Markets, HC Wainwright & Co., and HC Wainwright & Co. on September 12, 2024, August 12, 2024, and July 16, 2024, respectively. With an average price target of $13 between Northland Capital Markets, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 680.78% upside for Oncternal Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jul
0
0
0
0
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.8
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Northland Capital Markets
HC Wainwright & Co.
Cantor Fitzgerald
BTIG

1calculated from analyst ratings

Analyst Ratings for Oncternal Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Oncternal Therapeutics (ONCT) stock?

A

The latest price target for Oncternal Therapeutics (NASDAQ:ONCT) was reported by Northland Capital Markets on September 12, 2024. The analyst firm set a price target for $2.00 expecting ONCT to rise to within 12 months (a possible 20.12% upside). 10 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Oncternal Therapeutics (ONCT)?

A

The latest analyst rating for Oncternal Therapeutics (NASDAQ:ONCT) was provided by Northland Capital Markets, and Oncternal Therapeutics downgraded their market perform rating.

Q

When was the last upgrade for Oncternal Therapeutics (ONCT)?

A

The last upgrade for Oncternal Therapeutics Inc happened on December 4, 2023 when Brookline Capital raised their price target to $2. Brookline Capital previously had a hold for Oncternal Therapeutics Inc.

Q

When was the last downgrade for Oncternal Therapeutics (ONCT)?

A

The last downgrade for Oncternal Therapeutics Inc happened on September 12, 2024 when Northland Capital Markets changed their price target from N/A to $2 for Oncternal Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Oncternal Therapeutics (ONCT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncternal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncternal Therapeutics was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

Q

Is the Analyst Rating Oncternal Therapeutics (ONCT) correct?

A

While ratings are subjective and will change, the latest Oncternal Therapeutics (ONCT) rating was a downgraded with a price target of $0.00 to $2.00. The current price Oncternal Therapeutics (ONCT) is trading at is $1.67, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch